Analyzing Ra Pharmaceuticals (RARX) & Its Competitors
Ra Pharmaceuticals (NASDAQ: RARX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ra Pharmaceuticals to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, analyst recommendations and dividends.
Institutional & Insider Ownership
69.6% of Ra Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 14.5% of Ra Pharmaceuticals shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Ra Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ra Pharmaceuticals Competitors||882||3256||11745||235||2.70|
Ra Pharmaceuticals currently has a consensus price target of $25.00, suggesting a potential upside of 201.93%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.24%. Given Ra Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Ra Pharmaceuticals is more favorable than its rivals.
Risk & Volatility
Ra Pharmaceuticals has a beta of 4.75, indicating that its stock price is 375% more volatile than the S&P 500. Comparatively, Ra Pharmaceuticals’ rivals have a beta of 0.92, indicating that their average stock price is 8% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ra Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ra Pharmaceuticals||$4.93 million||-$28.86 million||-3.35|
|Ra Pharmaceuticals Competitors||$284.49 million||$34.10 million||77.91|
Ra Pharmaceuticals’ rivals have higher revenue and earnings than Ra Pharmaceuticals. Ra Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Ra Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ra Pharmaceuticals Competitors||-9,358.44%||-217.61%||-40.31%|
Ra Pharmaceuticals beats its rivals on 7 of the 13 factors compared.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.